Journal
NATURE IMMUNOLOGY
Volume 11, Issue 10, Pages 897-U1501Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ni.1935
Keywords
-
Categories
Funding
- National Health and Medical Research Council [516783]
- Science Foundation Ireland
- United States Department of Veterans Affairs
- US National Institutes of Health [DK-75998, AI063331]
- Crohn's and Colitis Foundation
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI063331, R01AI063331, R56AI063331] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK075998] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Interleukin 1 beta (IL-1 beta) is an important inflammatory mediator of type 2 diabetes. Here we show that oligomers of islet amyloid polypeptide (IAPP), a protein that forms amyloid deposits in the pancreas during type 2 diabetes, triggered the NLRP3 inflammasome and generated mature IL-1 beta. One therapy for type 2 diabetes, glyburide, suppressed IAPP-mediated IL-1 beta production in vitro. Processing of IL-1 beta initiated by IAPP first required priming, a process that involved glucose metabolism and was facilitated by minimally oxidized low-density lipoprotein. Finally, mice transgenic for human IAPP had more IL-1 beta in pancreatic islets, which localized together with amyloid and macrophages. Our findings identify previously unknown mechanisms in the pathogenesis of type 2 diabetes and treatment of pathology caused by IAPP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available